Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
24,015.20
(
0.00%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
100.92
(
2.66%
)
Bitcoin
74,283.54
(
-0.75%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 28
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 65606

Wednesday, 08/27/2008 9:22:59 AM

Wednesday, August 27, 2008 9:22:59 AM

Post# of 257250
>Apixaban did manage to show a statsig lower rate of clinically relevant bleeding (a safety rather than efficacy endpoint) relative to Lovenox, which bodes well for other Apixaban trials in VTE

These safety vs. efficacy results, makes me wonder if Apixaban's dose wasn't too low.


Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now